BioNTech starts buyback of up to USD 1.0 billion of ADSs, running to May 6, 2027

The program

BioNTech SE said in a 6-K filed June 8, 2026 that its Supervisory Board and Management Board authorized a share buyback program on May 7, 2026. The program covers American Depositary Shares, each representing one ordinary share, with a value of up to USD 1.0 billion. The buyback period begins on June 8, 2026 on the Nasdaq Global Select Market and runs up to and including May 6, 2027.

BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business, to enhance capital efficiency and to maintain financial flexibility. The 6-K does not say which obligations it means, and it gives no amount spent or number of ADSs bought as of the filing date.

The legal basis is the authorization granted by BioNTech's Annual General Meeting on May 17, 2024. That authorization lets the company acquire treasury shares until May 16, 2029, up to 10% of its share capital. The 6-K says the maximum number of shares it may repurchase under that authorization is 24.9 million.

Price limits and the broker

The buyback is run by a credit institution that BioNTech has mandated. The 6-K names no bank, broker or other institution, and it names no counsel or other advisor. The institution decides the timing of purchases independently of BioNTech, and the company says it will not influence those decisions. BioNTech can end the mandate, and the buyback may be stopped and restarted at any time under the applicable rules.

The 6-K sets price limits drawn from the German Stock Corporation Act. Where shares are bought on an exchange, the price may not exceed the volume-weighted average price of the last three trading days before a purchase by more than 10%, and may not fall below that average by more than 20%. The EU regulation the program follows bars buying above the higher of the last independent trade and the highest current independent bid, and caps purchases at 25% of average daily trading volume over the 20 trading days before each purchase.

The program is designed to comply with Rules 10b-18 and 10b5-1 under the U.S. Securities Exchange Act. BioNTech will disclose each transaction no later than the end of the seventh trading day after execution, in detailed and aggregated form, and will keep those disclosures on its website for at least five years.

Why the timing matters

BioNTech's annual report on Form 20-F, filed March 10, 2026, lists reduced demand for its COVID-19 vaccine among the factors that could affect its revenues and net profit. It also lists possible write-downs of inventory and costs for contract manufacturing capacity that becomes redundant. The buyback is announced against that background, and the 6-K does not connect the two.

The filing gives no cash balance and no statement of how the company will fund the full USD 1.0 billion. The pace is open-ended, since the mandated institution decides timing and the 6-K says the buyback may be stopped and continued at any time. The authorization sets a ceiling and is not a commitment to spend the full amount by May 2027.

The program also carries a definite legal limit. Under the 2024 authorization, the company may not repurchase more than 24.9 million shares, and the price band applies to every purchase. Those are the only hard figures in the filing, and they set the outer boundary of what the company can do under this program.

Report an error

Companies in this story

BNTXBioNTech SENASDAQ · GermanyOpen the desk